FIGURE 1.
FIGURE 2.
FIGURE 3.
Differences in scores of Slovenian version of Skull base inventory between patients with benign and malignant skull base tumours
| Benign tumour group (n = 35) | Malignant tumour group (n = 19) | p-value | |
|---|---|---|---|
| Total score | 75.6 ± 14.0 | 66.5 ± 15.0 | p = .031* |
| cognitive | 83.3 | 75.0 | p = .102** |
| emotional | 75.0 | 45.8 | p = .038** |
| family | 94.4 | 72.2 | p = .046** |
| financial | 83.3 | 66.7 | p = .058** |
| social | 65.4 ± 23.4 | 61.8 ± 21.7 | p = .591* |
| spiritual | 91.7 | 83.3 | p = .329** |
| endocrine | 87.5 | 87.5 | p = .862** |
| nasal | 67.3 ± 20.5 | 55.0 ± 24.5 | p = .056* |
| neurologic | 75.0 | 62.5 | p = .125** |
| visual | 83.3 | 70.8 | p = .075** |
| other | 75.0 | 58.3 | p = .008** |
Tumour types in the studied group
| Tumour type | n = 54 | % |
|---|---|---|
| Pituitary macroadenomab | 17 | 31.5 |
| Sinonasal cancerm | 12 | 22.2 |
| Nasopharyngeal cancerm | 4 | 7.4 |
| Olfactory meningiomab | 3 | 5.6 |
| Tuberculum sellae meningiomab | 3 | 5.6 |
| Metastasism | 2 | 3.7 |
| Petroclival meningiomab | 2 | 3.7 |
| Sellar meningiomab | 2 | 3.7 |
| Sphenoid sinus meningoencephaloceleb | 2 | 3.7 |
| Clival chordomam | 1 | 1.9 |
| Craniopharyngiomab | 1 | 1.9 |
| Infratemporal fossa schwannomab | 1 | 1.9 |
| Optic nerve germinomam | 1 | 1.9 |
| Rathke cleft cystb | 1 | 1.9 |
| Sellar teratomab | 1 | 1.9 |
| Skull base hemangiomab | 1 | 1.9 |